Pfizer Unveils Positive Results for VIZIMPRO® as first-line monotherapy in NSCLC patients

Pfizer Inc. on 25th Nov 2019, announced the efficacy and tolerability results from the subgroup analysis of Asian patien...

November 26, 2019 | Tuesday | News
Merck presented Data on Tepotinib for NSCLC at ESMO Asia 2019

Merck, a leading science and technology company, on 25 Nov 2019, announced the presentation of multiple abstracts on tep...

November 25, 2019 | Monday | News
BeiGene receives its first FDA approval

BeiGene, Ltd., China, a commercial-stage biopharmaceutical company focused on developing and commercializing innovative ...

November 18, 2019 | Monday | News
Yuhan Pharmaceuticals partners with Cyclica

South Korean healthcare company, Yuhan Pharmaceuticals (Yuhan) and Cyclica Inc. (Cyclica), a leading neo biotechnology c...

November 13, 2019 | Wednesday | News
China approves Alzheimer's drug

The State Food and Drug Administration of China (CFDA) has conditionally approved the application for the listing o...

November 11, 2019 | Monday | News
Samsung Biologics collaborates with Ichnos Sciences in derma space

South Korea headquartered Samsung Biologics has announced the signing of a long-term agreement with US based Ichnos Scie...

November 6, 2019 | Wednesday | News
EU approves BAVENCIO® (avelumab) Plus Axitinib to treat RCC

Merck and Pfizer Inc. on 29 Oct 2019, announced that the European Commission (EC) has approved BAVENCIO® (avelu...

October 29, 2019 | Tuesday | News
Biogen plans regulatory filing for Aducanumab for Alzheimer's

Biogen and Eisai, Co., Ltd. (Tokyo, Japan) has announced that, after consulting with the U.S. Food and Drug Administrati...

October 23, 2019 | Wednesday | News
Takeda acquires license for celiac disease therapy

Japanese firm Takeda Pharmaceutical Company  and US based COUR Pharmaceutical Development Company, Inc. have announ...

October 22, 2019 | Tuesday | News
NeuClone announces First Human dose of Stelara® (Ustekinumab) Biosimilar candidate

NeuClone, a clinical-stage biopharmaceutical company exclusively focused on developing high-quality biosimilar products,...

October 21, 2019 | Monday | News
Trastuzumab deruxtecan gets FDA priority review to treat metastatic breast cancer

AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo) have announced that the US Food and Drug Administration...

October 18, 2019 | Friday | News
Lilly's Migraine drug receives FDA approval

Eli Lilly and Company  has announced that the U.S. Food and Drug Administration (FDA) has approved REYVOW...

October 14, 2019 | Monday | News
Gilead Sciences submits NDA to treat RA in Japan

Gilead Sciences, Inc. has announced the New Drug Application (NDA) for filgotinib, an investigational, oral, select...

October 9, 2019 | Wednesday | News
Bayer and RIKEN establish partnership for novel drug discovery

Bayer AG (Bayer), and RIKEN Innovation Co., Ltd. (RIKEN Innovation), have entered into a strategic collaboration agreeme...

October 9, 2019 | Wednesday | News
Novo Nordisk set to bring innovative treatment for type 2 diabetes

Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) has approved Rybelsus® (semaglutide) ta...

September 23, 2019 | Monday | News
FDA approves combo drug to treat endometrial carcinoma

Eisai and Merck have announced that the U.S. Food and Drug Administration (FDA) approved the combination of LENVIMA, the...

September 19, 2019 | Thursday | News
FDA Grants Breakthrough Therapy Designation for Genentech’s Gazyva (Obinutuzumab)

Genentech, a member of the Roche Group has announced that the U.S. Food and Drug Administration (FDA) has granted Breakt...

September 18, 2019 | Wednesday | News
FDA grants priority review for Merck’s Ebola Vaccine

Merck, known as MSD outside the United States and Canada, has announced that the U.S. Food and Drug Administration (FDA)...

September 17, 2019 | Tuesday | Influencers

Podcast

Survey Box

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls